<li>albiglutide<p>lisinopril increases effects of albiglutide by unknown mechanism. Use Caution/Monitor. ACE inhibitors may increase hypoglycemic effect. Monitor glycemic control especially during the first month of treatment with an ACE inhibitor. .</p></li><li>aldesleukin<p>aldesleukin increases effects of lisinopril by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension.</p></li><li>alfuzosin<p>lisinopril, alfuzosin. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Exaggerated first dose hypotensive response.</p></li><li>aluminum hydroxide<p>aluminum hydroxide decreases effects of lisinopril by unspecified interaction mechanism. Use Caution/Monitor.</p></li><li>amifostine<p>amifostine increases effects of lisinopril by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension.</p></li><li>amiloride<p>lisinopril, amiloride. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of hyperkalemia.</p></li><li>amphetamine<p>amphetamine decreases effects of lisinopril by pharmacodynamic antagonism. Use Caution/Monitor.</p></li><li>asenapine<p>lisinopril, asenapine. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Exaggerated first dose hypotensive response.</p></li><li>aspirin<p>lisinopril, aspirin.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly with high dose aspirin, in elderly or volume depleted individuals.</p></li><li>aspirin/citric acid/sodium bicarbonate<p>aspirin/citric acid/sodium bicarbonate decreases effects of lisinopril by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.<span><br><br></span>lisinopril, aspirin/citric acid/sodium bicarbonate.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>avanafil<p>avanafil increases effects of lisinopril by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension.</p></li><li>azathioprine<p>lisinopril, azathioprine. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of neutropenia.</p></li><li>bumetanide<p>lisinopril, bumetanide. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of acute hypotension, renal insufficiency.</p></li><li>calcium carbonate<p>calcium carbonate decreases effects of lisinopril by unspecified interaction mechanism. Use Caution/Monitor.</p></li><li>canagliflozin<p>lisinopril and canagliflozin both increase  serum potassium. Use Caution/Monitor.</p></li><li>carbidopa<p>carbidopa increases effects of lisinopril by pharmacodynamic synergism. Use Caution/Monitor. Therapy with carbidopa, given with or without levodopa or carbidopa-levodopa combination products, is started, dosage adjustment of the antihypertensive drug may be required.</p></li><li>celecoxib<p>lisinopril, celecoxib.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>chlorpropamide<p>lisinopril increases effects of chlorpropamide by pharmacodynamic synergism. Use Caution/Monitor.</p></li><li>choline magnesium trisalicylate<p>lisinopril, choline magnesium trisalicylate.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>cyclosporine<p>lisinopril, cyclosporine. Mechanism: unspecified interaction mechanism. Use Caution/Monitor. Risk of acute renal failure.</p></li><li>dalteparin<p>dalteparin increases toxicity of lisinopril by Other (see comment). Use Caution/Monitor. 
Comment: Low molecular weight heparins may suppress adrenal aldosterone secretion, which can potentially cause hyperkalemia.</p></li><li>diclofenac<p>lisinopril, diclofenac.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>diflunisal<p>lisinopril, diflunisal.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>digoxin<p>lisinopril increases levels of digoxin by unspecified interaction mechanism. Use Caution/Monitor.</p></li><li>doxazosin<p>lisinopril, doxazosin. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Exaggerated first dose hypotensive response.</p></li><li>drospirenone<p>lisinopril, drospirenone. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of hyperkalemia.</p></li><li>enoxaparin<p>enoxaparin increases toxicity of lisinopril by Other (see comment). Use Caution/Monitor. 
Comment: Low molecular weight heparins may suppress adrenal aldosterone secretion, which can potentially cause hyperkalemia.</p></li><li>eplerenone<p>lisinopril, eplerenone. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of hyperkalemia.</p></li><li>ethacrynic acid<p>lisinopril, ethacrynic acid. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of acute hypotension, renal insufficiency.</p></li><li>etodolac<p>lisinopril, etodolac.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>everolimus<p>lisinopril, everolimus.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: Coadministration increases risk of angioedema.</p></li><li>exenatide injectable solution<p>lisinopril increases effects of exenatide injectable solution by Other (see comment). Use Caution/Monitor. 
Comment: ACE inhibitors may increase hypoglycemic effect. Monitor glycemic control especially during the first month of treatment with an ACE inhibitor. .</p></li><li>exenatide injectable suspension<p>lisinopril increases effects of exenatide injectable suspension by Other (see comment). Use Caution/Monitor. 
Comment: ACE inhibitors may increase hypoglycemic effect. Monitor glycemic control especially during the first month of treatment with an ACE inhibitor.</p></li><li>fenoprofen<p>lisinopril, fenoprofen.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>flurbiprofen<p>lisinopril, flurbiprofen.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>furosemide<p>lisinopril, furosemide. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of acute hypotension, renal insufficiency.</p></li><li>glimepiride<p>lisinopril increases effects of glimepiride by pharmacodynamic synergism. Use Caution/Monitor.</p></li><li>glipizide<p>lisinopril increases effects of glipizide by pharmacodynamic synergism. Use Caution/Monitor.</p></li><li>gliquidone<p>lisinopril increases effects of gliquidone by pharmacodynamic synergism. Use Caution/Monitor.</p></li><li>glyburide<p>lisinopril increases effects of glyburide by pharmacodynamic synergism. Use Caution/Monitor.</p></li><li>gold sodium thiomalate<p>lisinopril, gold sodium thiomalate. Mechanism: unspecified interaction mechanism. Use Caution/Monitor. Combo of ACE inhibitors and injectable gold has caused rare cases of nitritoid reaction (flushing, N/V, hypot'n).</p></li><li>heparin<p>heparin increases toxicity of lisinopril by Other (see comment). Use Caution/Monitor. 
Comment: Low molecular weight heparins may suppress adrenal aldosterone secretion, which can potentially cause hyperkalemia.</p></li><li>ibuprofen<p>lisinopril, ibuprofen.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>indomethacin<p>lisinopril, indomethacin.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>insulin aspart<p>lisinopril increases effects of insulin aspart by pharmacodynamic synergism. Use Caution/Monitor.</p></li><li>insulin degludec<p>lisinopril, insulin degludec.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Both drugs decrease blood glucose.</p></li><li>insulin degludec/insulin aspart<p>lisinopril, insulin degludec/insulin aspart.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Both drugs decrease blood glucose.</p></li><li>insulin detemir<p>lisinopril increases effects of insulin detemir by pharmacodynamic synergism. Use Caution/Monitor.</p></li><li>insulin glargine<p>lisinopril increases effects of insulin glargine by pharmacodynamic synergism. Use Caution/Monitor.</p></li><li>insulin glulisine<p>lisinopril increases effects of insulin glulisine by pharmacodynamic synergism. Use Caution/Monitor.</p></li><li>insulin inhaled<p>lisinopril, insulin inhaled.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Both drugs decrease blood glucose.</p></li><li>insulin lispro<p>lisinopril increases effects of insulin lispro by pharmacodynamic synergism. Use Caution/Monitor.</p></li><li>insulin nph<p>lisinopril increases effects of insulin nph by pharmacodynamic synergism. Use Caution/Monitor.</p></li><li>insulin regular human<p>lisinopril increases effects of insulin regular human by pharmacodynamic synergism. Use Caution/Monitor.</p></li><li>ketoprofen<p>lisinopril, ketoprofen.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>ketorolac<p>lisinopril, ketorolac.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>ketorolac intranasal<p>lisinopril, ketorolac intranasal.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>lanthanum carbonate<p>lanthanum carbonate decreases levels of lisinopril by cation binding in GI tract. Use Caution/Monitor. Administer ACE inhibitor at least 2 hr before or after lanthanum.</p></li><li>levodopa<p>levodopa increases effects of lisinopril by pharmacodynamic synergism. Use Caution/Monitor. Consider decreasing dosage of antihypertensive agent.</p></li><li>liraglutide<p>lisinopril increases effects of liraglutide by unknown mechanism. Use Caution/Monitor. ACE inhibitors may increase hypoglycemic effect. Monitor glycemic control especially during the first month of treatment with an ACE inhibitor. .</p></li><li>lithium<p>lisinopril increases toxicity of lithium by unknown mechanism. Use Caution/Monitor. ACE inhibitor induced Na+ depletion may increase reabsorption of lithium from renal tubule.</p></li><li>lurasidone<p>lurasidone increases effects of lisinopril by Other (see comment). Use Caution/Monitor. 
Comment: Potential  for increased risk of hypotension with concurrent use. Monitor blood pressure and adjust  dose of  antihypertensive agent as needed.</p></li><li>maraviroc<p>maraviroc, lisinopril.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of orthostatic hypotension.</p></li><li>meclofenamate<p>lisinopril, meclofenamate.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>mefenamic acid<p>lisinopril, mefenamic acid.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>meloxicam<p>lisinopril, meloxicam.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>mipomersen<p>mipomersen, lisinopril.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: Both drugs have potential to increase hepatic enzymes; monitor LFTs.</p></li><li>moxisylyte<p>lisinopril, moxisylyte. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Exaggerated first dose hypotensive response.</p></li><li>nabumetone<p>lisinopril, nabumetone.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>naproxen<p>lisinopril, naproxen.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>nesiritide<p>nesiritide, lisinopril.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Additive hypotensive effects.</p></li><li>nitroglycerin rectal<p>nitroglycerin rectal, lisinopril.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Observe for possible additive hypotensive effects during concomitant use. .</p></li><li>oxaprozin<p>lisinopril, oxaprozin.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>phenoxybenzamine<p>lisinopril, phenoxybenzamine. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Exaggerated first dose hypotensive response.</p></li><li>phentolamine<p>lisinopril, phentolamine. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Exaggerated first dose hypotensive response.</p></li><li>piroxicam<p>lisinopril, piroxicam.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>potassium acid phosphate<p>lisinopril increases levels of potassium acid phosphate by decreasing elimination. Use Caution/Monitor. Risk of hyperkalemia.</p></li><li>potassium chloride<p>lisinopril increases levels of potassium chloride by decreasing elimination. Use Caution/Monitor. Risk of hyperkalemia.</p></li><li>potassium citrate<p>lisinopril increases levels of potassium citrate by decreasing elimination. Use Caution/Monitor. Risk of hyperkalemia.</p></li><li>potassium citrate/citric acid<p>lisinopril and potassium citrate/citric acid both increase  serum potassium. Use Caution/Monitor.</p></li><li>prazosin<p>lisinopril, prazosin. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Exaggerated first dose hypotensive response.</p></li><li>salsalate<p>lisinopril, salsalate.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>silodosin<p>lisinopril, silodosin. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Exaggerated first dose hypotensive response.</p></li><li>sirolimus<p>lisinopril, sirolimus.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: Coadministration increases risk of angioedema.</p></li><li>sodium bicarbonate<p>sodium bicarbonate decreases effects of lisinopril by unspecified interaction mechanism. Use Caution/Monitor.</p></li><li>sodium citrate/citric acid<p>sodium citrate/citric acid decreases effects of lisinopril by unspecified interaction mechanism. Use Caution/Monitor.</p></li><li>spironolactone<p>lisinopril, spironolactone. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of hyperkalemia.</p></li><li>sulfasalazine<p>sulfasalazine decreases effects of lisinopril by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.<span><br><br></span>lisinopril, sulfasalazine.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>sulindac<p>lisinopril, sulindac.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>tadalafil<p>tadalafil increases effects of lisinopril by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension.</p></li><li>temsirolimus<p>lisinopril, temsirolimus.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: Coadministration increases risk of angioedema.</p></li><li>terazosin<p>lisinopril, terazosin. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Exaggerated first dose hypotensive response.</p></li><li>tinzaparin<p>tinzaparin increases toxicity of lisinopril by Other (see comment). Use Caution/Monitor. 
Comment: Low molecular weight heparins may suppress adrenal aldosterone secretion, which can potentially cause hyperkalemia.</p></li><li>tolazamide<p>lisinopril increases effects of tolazamide by pharmacodynamic synergism. Use Caution/Monitor.</p></li><li>tolbutamide<p>lisinopril increases effects of tolbutamide by pharmacodynamic synergism. Use Caution/Monitor.</p></li><li>tolmetin<p>lisinopril, tolmetin.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>torsemide<p>lisinopril, torsemide. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of acute hypotension, renal insufficiency.</p></li><li>triamterene<p>lisinopril, triamterene. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of hyperkalemia.</p></li><li>trimethoprim<p>trimethoprim and lisinopril both increase  serum potassium. Use Caution/Monitor. Trimethoprim decreases urinary potassium excretion. May cause hyperkalemia, particularly with high doses, renal insufficiency, or when combined with other drugs that cause hyperkalemia.</p></li><li>xipamide<p>xipamide increases effects of lisinopril by pharmacodynamic synergism. Use Caution/Monitor.</p></li><li>zotepine<p>lisinopril, zotepine. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Exaggerated first dose hypotensive response.</p></li>